- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03824990
Multi-center Clinical Study on Neonatal Hyperbilirubinemia
October 29, 2021 updated by: Zhangbin Yu, Nanjing Medical University
Multi-center Clinical Study on Early Screening and Treatment of Hyperbilirubinemia of Term and Late-preterm Neonates
Eight hospitals in China will participate in the study, which aims to decrease the incidence of severe hyperbilirubinemia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Through a prospective cohort study of healthy term and near-term infants, the study tries to truly reflect the epidemiology, intervention status, and outcomes of neonatal hyperbilirubinemia and the cost.
Hopefully, by improving the quality of management of neonatal jaundice,we can explore and obtain a healthy term and near-term jaundice management model suitable for China's national condition, which can eventually reduce the incidence rate of neonatal severe hyperbilirubinemia and bilirubin encephalopathy.
Study Type
Interventional
Enrollment (Actual)
20000
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Nanjing Maternity and Child Health Care Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 4 weeks (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
term or near-term neonates with gestational age ≥35w and birth weight ≥2000g.
Exclusion Criteria:
Infants admitted to a higher level of intervention before discharge.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
NO_INTERVENTION: Before-intervention phase
All the healthy infants who were admitted from March 2018 to August 2018 to the Well Baby nurse of different hospitals.
|
|
|
EXPERIMENTAL: Intervention phase
All the healthy infants who were admitted from September 2018 to February 2019 to the Well Baby nurse of different hospitals.During this phase,multiple intervention bundles of quality improvement will be implemented.
|
During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
|
|
EXPERIMENTAL: Sustainability intervention phase
All the healthy infants who were admitted from March 2019 to August 2019 to the Well Baby nurse of different hospitals.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
|
During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incidence of bilirubin encephalopathy
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The incidence of severe hyperbilirubinemia
Time Frame: 18 months
|
Severe hyperbilirubinemia:total serum bilirubin more than 20mg/dL
|
18 months
|
|
The rate of lost to follow-up
Time Frame: 18 months
|
The rate of lost to follow-up for jaundice after discharge from well-baby nursery
|
18 months
|
|
The incidence of adverse neurological outcomes in patients with severe hyperbilirubinemia
Time Frame: 42 months
|
Patients with severe hyperbilirubinemia from 11 hospitals will be followed to investigate their neurological outcomes until 24 months after birth
|
42 months
|
|
Medical costs in patients with severe hyperbilirubinemia
Time Frame: 18 months
|
To compare the medical costs in patients with severe hyperbilirubinemia from 3 phases of quality improvement.
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Zhiyong Sun, PHD, JiLin Women and Children Health Hospital
- Principal Investigator: Haiyan Cai, PHD, Qinhuangdao Maternal and Child Health Care Hospital
- Principal Investigator: Yonghui Yu, MD, Shandong Provincial Hospital
- Principal Investigator: Xin Yuan, MD, Shan Dong Qian Fo Shan Hospital
- Principal Investigator: Jin Qian, MD, Shan Dong Liao Cheng Hospital
- Principal Investigator: Wenyan Tang, PHD, Jiangxi Maternal and Child Health Hospital
- Principal Investigator: Zhankui Li, PHD, Northwest Women's and Children's Hospital, Xi'an, Shaanxi
- Principal Investigator: Jie Gu, PHD, Yin Chuan Maternity and Child Health Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
March 1, 2018
Primary Completion (ACTUAL)
August 31, 2021
Study Completion (ACTUAL)
October 15, 2021
Study Registration Dates
First Submitted
January 30, 2019
First Submitted That Met QC Criteria
January 30, 2019
First Posted (ACTUAL)
January 31, 2019
Study Record Updates
Last Update Posted (ACTUAL)
November 1, 2021
Last Update Submitted That Met QC Criteria
October 29, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NMU-FY2018-72
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.